MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide June 12, 2026 8:00 AM EDT
Company Participants
Pete De Spain – Senior Vice President of Investor Relations & Corporate Communications
Peter Hawryluk – CEO, President & Director
Salomon Azoulay – Chief Medical Officer
Mark Soued – Chief Commercial Officer
Conference Call Participants
Richard DiMarchi
Michael T. Collins
Seamus Fernandez – Guggenheim Securities, LLC, Research Division
Tyler Van Buren – TD Cowen, Research Division
Michael Yee – UBS Investment Bank, Research Division
Jiale Song – Jefferies LLC, Research Division
Jessica Fye – JPMorgan Chase & Co, Research Division
Eliana Merle – Barclays Bank PLC, Research Division
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Srikripa Devarakonda – Truist Securities, Inc., Research Division
Presentation
Pete De Spain
Senior Vice President of Investor Relations & Corporate Communications
Greetings, and welcome to the MBX Biosciences Business Update Call. [Operator Instructions]. As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. Kent Hawryluk, President, CEO and Co-Founder of MBX Biosciences. Please go ahead, sir.
Peter Hawryluk
CEO, President & Director
Good morning, and thank you for joining us to review the once-weekly Canvuparatide 1-year data from the Phase II open-label extension study. I am Kent Hawryluk, President and CEO of MBX. I want to remind everyone that this presentation includes forward-looking statements. I encourage you to review the risk factors and other disclosures in our most recent SEC filings available on the MBX website. I’m pleased to be joined today by esteemed colleagues, including Dr. Richard DiMarchi, MBX Scientific Co-Founder and my business partner for the past 23 years. Richard and I started MBX with a sense of urgency to give back freedom to people with hypoparathyroidism through a PTH replacement therapy that’s patient-friendly and once weekly just as patients have today in major diseases but not
